Navigation Links
Data from Two Pivotal Trials of AMRIX, a New Once-Daily Extended-Release Muscle Relaxant, Presented at the American Academy of Pain Medicine Meeting
Date:2/14/2008

Data Showed AMRIX is Superior to Placebo, Similar Efficacy to Immediate Release Formulation Taken Three Times a Day, and Less Daytime Drowsiness

FRAZER, Pa., Feb. 14 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced the pooled analysis of two pivotal randomized, placebo-controlled clinical trials showing that AMRIX(R) (cyclobenzaprine hydrochloride extended-release capsules), a new once-daily extended-release skeletal muscle relaxant, was superior to placebo. AMRIX had similar efficacy to cyclobenzaprine immediate-release (CIR) taken three times a day in alleviating acute muscle spasm associated with lower back and neck pain. In addition, less daytime drowsiness was observed with AMRIX compared to CIR, although such a comparison was not pre-specified in the statistical analysis plan. These results were presented today at the 24th Annual Meeting of the American Academy of Pain Medicine in Orlando, FL.

"Typically, muscle relaxants are taken multiple times a day, which can make it difficult for some of my patients with acute muscle spasm associated with lower back and neck pain to adhere to their treatment regimen," said Arnold J. Weil, MD, of Non-Surgical Orthopaedics in Atlanta, GA, and the lead investigator in these studies. "With data supporting AMRIX as an effective once-daily treatment, health care professionals now have an easy-to-administer treatment option to offer their patients who are suffering from acute muscle spasm."

The data, which were the basis for the U.S. Food and Drug Administration approval of AMRIX, were pooled from two identical 14-day randomized, double-blind, placebo-controlled, multicenter studies, evaluating a total of 504 adults across four study arms (AMRIX 15 mg, AMRIX 30 mg, placebo, and CIR 10 mg three times daily). These participants had moderate-to-severe muscle spasm of cervical or lumbar origin associated with local pain, tenderness, limitation of motion, and restrictions of daily living. In these studies, patients and physicians assessed how helpful the medication was in the treatment of acute muscle spasm. Primary endpoints of the clinical trials were Patient's Rating of Medication Helpfulness at day four of treatment and Physician's Clinical Global Assessment at day four.

Study results of the Patient's Rating of Medication Helpfulness, a measure of efficacy, showed that a higher proportion of patients (p<0.025) taking AMRIX 15 mg (56.0 percent; n=116) and AMRIX 30 mg (56.7 percent; n=120) reported "good" to "excellent" responses compared with the placebo group (40.0 percent; n=115) at day four. The distribution of responses for AMRIX and CIR was similar. The trials did not demonstrate significant differences among the study groups on the Physician's Clinical Global Assessment at day four.

In a scale of Patient-Rated Daytime Drowsiness at day four, more patients in the AMRIX groups (15 mg, 50.4 percent, and 30 mg, 42.1 percent) had "no to very little" drowsiness compared with the CIR group (28.8 percent). As expected, more patients in the AMRIX groups had daytime drowsiness compared with placebo.

The majority of all adverse events reported in these trials were mild in intensity. The most common side effects of AMRIX (greater than or equal to three percent) were dry mouth, dizziness, fatigue, nausea, and constipation. Somnolence (a state of drowsiness) was the most common adverse event leading to discontinuation (two patients in the AMRIX 30 mg group and eight in the CIR group).

About AMRIX

AMRIX is indicated for short-term use (up to two or three weeks) for relief of muscle spasm associated with acute, painful musculoskeletal conditions. The first and only once-daily muscle relaxant, AMRIX is available in 15 and 30 mg dosage strengths.

AMRIX is contraindicated with concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation; in patients during the acute recovery phase of myocardial infarction; in patients with arrhythmias, heart block conduction disturbances, or congestive heart failure; and in patients with hyperthyroidism. AMRIX may enhance the effects of alcohol, barbiturates, and other CNS depressants. AMRIX should not be used in elderly patients or in patients with impaired hepatic function. AMRIX should be used with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic medication.

For complete product information, visit http://www.amrix.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, AMRIX, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results, particularly with respect to the AMRIX clinical trials; manufacturing development and capabilities; market prospects for its products; sales and earnings guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward- looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
2. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
3. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
4. Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer
5. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
9. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
10. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
11. ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... 2016 , ... After several promising treatments in Panama using ... of Knowledge in Panama, a 6 year-old Duchenne’s muscular dystrophy patient received his ... following FDA approval of a second application for a single patient, investigational new ...
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci has ... in leading laboratories all over the globe. Their cute firefly logo has been ... awesome cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. These ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... delegation at BIO 2016 in San Francisco. Located at booth number 7301, representatives ... to answer questions and discuss the Thai biotechnology and life sciences sector. ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... recently became double board-certified in surgery and surgery of the hand by the ... is no stranger to going above and beyond in his pursuit of providing ...
Breaking Biology Technology:
(Date:3/15/2016)... York , March 15, 2016 ... market report published by Transparency Market Research "Digital Door Lock ... and Forecast 2015 - 2023," the global digital door lock ... 731.9 Mn in 2014 and is forecast to grow at ... Growth of micro, small and medium enterprises (MSMEs) across the ...
(Date:3/11/2016)... , March 11, 2016 ... new market research report "Image Recognition Market by Technology ... (Marketing and Advertising), by Deployment Type (On-Premises and Cloud), ... To 2022", published by MarketsandMarkets, the global market is ... to USD 29.98 Billion by 2020, at a CAGR ...
(Date:3/9/2016)... March 9, 2016  Crossmatch ® , a ... solutions, today announced the addition of smart features ... multi-factor authentication platform. New contextual and application-specific ... step-up security where it,s needed most — while ... DC . --> Washington, ...
Breaking Biology News(10 mins):